Logan Coy Related postsA Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)September 11, 2026A Multicenter, Randomized, Open-label, Phase 2 Study of BMS-986504 Monotherapy in Advanced or Metastatic NSCLC with Homozygous MTAP Deletion After Progression on Prior TherapiesSeptember 11, 2026A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Bleximenib, Venetoclax and Azacitidine for Newly Diagnosed AML Harboring KMT2A Rearrangements or NPM1 Mutations Ineligible for Intensive ChemotherapySeptember 11, 2026 Previous postRandomized, open-label study of the BRIA-IMT regimen and checkpoint inhibitor vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC)Next postSubstudy ASPEN-09-03: A Single-arm Phase 2 Study of Evorpacept with Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (ASPEN-09-03), Protocol AT148009